Results 271 to 280 of about 48,636 (310)

Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia

American Journal of Hematology, 1992
AbstractThe surface antigens expressed by the cells of chronic lymphocytic leukemia (CLL) are well known. Most CLL are monoclonal B‐cell lymphoproliferative disorders characterized by the coexpression of B‐cell antigens and CD5, an antigen present predominantly on T cells.
N M, Almasri, R E, Duque, J, Iturraspe, E, Everett, R C, Braylan   +4 more
openaire   +2 more sources

GM-CSF does not increase CD20 antigen expression on chronic lymphocytic leukemia lymphocytes

Leukemia Research, 2005
CD20 antigen expression in B-chronic lymphocytic leukemia (B-CLL) is at significantly lower levels than in non-Hodgkins lymphoma, which may affect the degree of anti-CD20 antibody binding. Low density of CD20 expression on malignant cells may explain the lower response rates to anti-CD20 monoclonal antibody, observed in B-CLL.
Yagci, M, Akar, I, Sucak, GT, Haznedar, R   +3 more
openaire   +3 more sources

Target cell killing effects of CD20 targeting chimeric antigen receptor T cells derived from the type II anti-CD20 antibody.

Journal of Clinical Oncology, 2017
e14548 Background: Chimeric Antigen Receptor T cells (CAR-Ts) targeting CD19 have shown very promising clinical outcomes in treatment of B-cell linage hematological malignancies. However, many patients with relapsed diseases were found to have down-regulated/loss of CD19 surface expression after CD19 CAR-T therapy.
Yihong Yao, Xin Yao, Shigui Zhu, Wei Zhu, Zhiyuan Li, Qingxia Wang, Lin Zhu, Anyun Ma, Yanfeng Li, Yutian Wei, Chengxiang Dai, Li Zhang, Jiaqi Huang, Bizuo Liu   +13 more
openaire   +1 more source

The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders

Expert Opinion on Biological Therapy, 2011
Immunotherapy using an antibody (rituximab) targeting CD20 antigen in combination with chemotherapy has been recently associated with significantly improved response rate and survival in patients with various types of CD20-positive B-cell lymphoproliferative disorders. This treatment may induce the disappearance of CD20 surface expression on neoplastic
Musto P, D'Auria F
openaire   +2 more sources

Effect of interferon-α on CD20 antigen expression of B–cell chronic lymphocytic leukemia

Cytokines, Cellular & Molecular Therapy, 2000
Chimeric CD20 monoclonal antibody as alternative therapy in relapsed low-grade non-Hodgkin's lymphoma (NHL) has produced responses in nearly 50% of patients. Augmenting CD20 expression on tumor cells and/or inducing its expression may increase the cell kill and effectiveness of antibody therapy. Peripheral blood lymphocytes from 19 patients with B-cell
S, Sivaraman, P, Venugopal, R, Ranganathan, C G, Deshpande, X, Huang, A, Jajeh, S A, Gregory, T, O'Brien, H D, Preisler   +8 more
openaire   +2 more sources

Development and Characterization of a New Antipeptide Monoclonal Antibody Directed to Human CD20 Antigen

Cancer Biotherapy and Radiopharmaceuticals, 2015
The rapid expansion of immunotherapeutic approaches for treatment of various diseases, including cancers, has been greatly facilitated by the invention of new generation of antibodies. Clinical studies have indicated that anti-CD20 mAb-based therapies represent an effective treatment for various diseases with overexpression of CD20 on their cell ...
Mahdi, Habibi-Anbouhi, Kayhan, Azadmanesh, Mahdi, Behdani, Ensiyeh, Hajizadeh-Saffar, Rouhollah, Vahabpour, Mohammad Ali, Shokrgozar   +5 more
openaire   +2 more sources

Construction and Characterizationc of a Camelized, Human, VH-based Peptide Vaccine Against CD20 Antigen

Immunotherapy, 2013
The purpose of this study was to construct and characterize a camelized, human, heavy-chain variable (VH) fragment-based peptide vaccine against CD20 antigen.Camelized, human VH with improved solubility and stability was used as a vaccine scaffold. A CD20 B-cell epitope was introduced into the complementarity determining region 3 of the engineered VH ...
Jianbin, Liu, Yanguo, Tan, Ranxing, Zhang   +2 more
openaire   +2 more sources

Abstract IA12: Combating antigen escape with CD19/CD20 bispecific CAR-T cell therapy

Cancer Immunology Research, 2017
Abstract T cells expressing chimeric antigen receptors (CARs) specific for the B-cell marker CD19 have shown impressive results in the treatment of B-cell malignancies. However, multiple clinical trials have also demonstrated the vulnerability of single-input CD19 CAR-T cell therapy to antigen escape, in which patients relapse with the ...
Eugenia Zah, Meng-Yin Lin, Michael C. Jensen, Anne Silva-Benedict, Yvonne Y. Chen   +4 more
openaire   +1 more source

Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.

Clinical cancer research : an official journal of the American Association for Cancer Research, 1999
Rituximab is a chimeric antibody with human gamma-1 and kappa constant regions and murine variable regions. It recognizes the CD20 antigen, a pan B-cell marker. Therapeutic trials in patients with B-cell non-Hodgkin's lymphoma (NHL) have shown significant efficacy with a primary response rate of 50%, and a secondary response rate of 44% after repeat ...
T A, Davis, D K, Czerwinski, R, Levy
openaire   +1 more source

CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis.

Human antibodies, 2011
Visualization of the CD20-antigen expression could provide a tool to localize sites of inflammation and could be of additive value in the diagnosis, and subsequently, in the treatment follow-up of patients with rheumatoid arthritis. In this study, an anti-CD20 monoclonal antibody, rituximab (Mabthera®), was radiolabeled with ¹²⁴Iodine.
L, Tran, A D R, Huitema, M H, van Rijswijk, H J, Dinant, J W, Baars, J H, Beijnen, W V, Vogel   +6 more
openaire   +2 more sources